Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Nearly 200 participants from 50 Unani Academia and Council participated
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Subscribe To Our Newsletter & Stay Updated